ASH 2023 | HRQoL in heavily pretreated patients with MM treated with ide-cel or standard regimens in KarMMa-3

Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, presents the findings of a sub-analysis of the KarMMa-3 trial (NCT03651128), which focused on comparing health-related quality of life (HRQoL) parameters in heavily pretreated patients with relapsed/refractory (R/R) multiple myeloma (MM) who were treated with idecabtagene vicleucel (ide-cel) or standard regimens. HRQoL was assessed using several validated methods – the European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30), EORTC Quality of Life Questionnaire Multiple Myeloma Module (QLQ-MY20), and EQ-5D-5L. Ide-cel was found to have a significant and clinically relevant effect on the HRQoL of patients, and this was seen even in the most heavily pretreated patients who had received a minimum of 3 prior lines of therapy. These findings add to the evidence favoring a single infusion of CAR T-cell therapy over continuous standard treatment in patients with MM. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.